

## Development and validation of the MMCD score to predict kidney replacement therapy in COVID-19 patients

### Authors:

Flávio de Azevedo Figueiredo MD<sup>1,2</sup> (Figueiredo FA, [flavio.figueiredo@ufla.br](mailto:flavio.figueiredo@ufla.br); 0000-0002-3100-2565)

Lucas Emanuel Ferreira Ramos<sup>3</sup> (Ramos LEF, [luckermos19@gmail.com](mailto:luckermos19@gmail.com); 0000-0001-7844-0581)

Rafael Tavares Silva<sup>3</sup> (Silva RT, [rafaelsilva@posteo.net](mailto:rafaelsilva@posteo.net); 0000-0002-9270-5328)

Magda Carvalho Pires<sup>3</sup> PhD (Pires MC, [magda@est.ufmg.br](mailto:magda@est.ufmg.br); 0000-0003-3312-4002)

Daniela Ponce MD, PhD<sup>4</sup> (Ponce D, [daniela.ponce@unesp.br](mailto:daniela.ponce@unesp.br); 0000-0002-6178-6938)

Rafael Lima Rodrigues de Carvalho<sup>24</sup> PhD (Carvalho RLR, [rafaelsjdr@hotmail.com](mailto:rafaelsjdr@hotmail.com); 0000-0003-3576-3748)

Alexandre Vargas Schwarzbald<sup>5</sup> MD, PhD (Schwarzbald AV, [alexvspoa@gmail.com](mailto:alexvspoa@gmail.com); 0000-0002-5535-6288)

Amanda de Oliveira Maurílio<sup>6</sup> MD (Maurílio AO, [amandaoliveira.maurilio@gmail.com](mailto:amandaoliveira.maurilio@gmail.com); 000-0002-9355-9596)

Ana Luiza Bahia Alves Scotton<sup>7</sup> MD (Scotton ALBA, [analuiza.bahia@yahoo.com.br](mailto:analuiza.bahia@yahoo.com.br); 0000-0002-5857-2031)

Andresa Fontoura Garbini<sup>8</sup> B.Sc (Garbini AF, [andrygarbini@hotmail.com](mailto:andrygarbini@hotmail.com); 0000-0002-3467-2150)

Bárbara Lopes Farace<sup>9</sup> MD (Farace BL, [barbarafarace@gmail.com](mailto:barbarafarace@gmail.com); 000-0002-6172-1093)

Bárbara Machado Garcia<sup>10</sup> (Garcia BM, [barbaramgarcia1234@gmail.com](mailto:barbaramgarcia1234@gmail.com);  
0000-0001-6538-9086)

Carla Thais Cândida Alves da Silva<sup>11</sup> (Silva CTCA, [carlatcas@gmail.com](mailto:carlatcas@gmail.com);  
0000-0003-1726-4494)

Christiane Corrêa Rodrigues Cimini<sup>12,13</sup> MD, MSc (Cimini CCR,  
[christiane.cimini@gmail.com](mailto:christiane.cimini@gmail.com); 0000-0002-1973-1343)

Cíntia Alcantara de Carvalho<sup>14</sup> B.Sc (Carvalho CA,  
[carvalho.cintiaa@gmail.com](mailto:carvalho.cintiaa@gmail.com); 0000-0001-8240-2481)

Cristiane dos Santos Dias<sup>15</sup> MD, MSc, PhD (Dias CS, [cristianedias@ufmg.br](mailto:cristianedias@ufmg.br);  
0000-0001-6559-3300)

Daniel Vitorio Silveira<sup>16</sup> MD, MSc (Silveira DV, [danielvez@gmail.com](mailto:danielvez@gmail.com); 0000-  
0002-7381-1651)

Euler Roberto Fernandes Manenti<sup>17</sup> MD, PhD (Manenti ERF,  
[eulermanenti@gmail.com](mailto:eulermanenti@gmail.com); 0000-0003-1592-4727)

Evelin Paola de Almeida Cenci<sup>18</sup> B.Sc (Cenci EPA,  
[assistencial6\\_hu@centrodepesquisaclinica.com.br](mailto:assistencial6_hu@centrodepesquisaclinica.com.br); 0000-0001-8548-9279)

Fernando Anschau<sup>8</sup> MD, PhD (Anschau F, [afernando@ghc.com.br](mailto:afernando@ghc.com.br); 0000-  
0002-2657-5406)

Fernando Graça Aranha<sup>19</sup> MD (Aranha FG, [fgranha@icloud.com](mailto:fgranha@icloud.com); 0000-  
0001-9173-8892)

Filipe Carrilho de Aguiar<sup>20</sup> MD (Aguiar FC, [filipe.carrilhoag@gmail.com](mailto:filipe.carrilhoag@gmail.com);  
0000-0002-8277-2631)

Frederico Bartolazzi<sup>11</sup> MD, MSc (Bartolazzi F, [fredlazzi@hotmail.com](mailto:fredlazzi@hotmail.com); 0000-  
0002-9696-4685)

Giovanna Grunewald Vietta<sup>19</sup> MD, PhD (Vietta GG, ggvietta@gmail.com; 0000-0002-0756-3098)

Guilherme Fagundes Nascimento<sup>16</sup> MD, MSc (Nascimento GF, guilhermefagundesn@hotmail.com; 0000-0001-9064-7067)

Helena Carolina Noal<sup>5</sup> MSc (Noal HC, helenacnoal@gmail.com; 0000-0001-9912-2881)

Helena Duani<sup>21</sup> MD, PhD (Duani H, hduani@yahoo.com.br; 0000-0001-9345-018X)

Heloisa Reniers Vianna<sup>22</sup> MD, MSc (Vianna HR, hrvianna@hotmail.com; 0000-0003-1144-6262)

Henrique Cerqueira Guimarães<sup>9</sup> MD, PhD (Guimarães HC, hcerqueirag@gmail.com; 0000-0001-6511-7400)

Joice Coutinho de Alvarenga<sup>14</sup> MD (Alvarenga JC, joice-alvarenga@hotmail.com; 0000-0003-3536-7112)

José Miguel Chatkin<sup>23</sup> MD, PhD (Chatkin JM, jmchatkin@puccs.br; 0000-0002-4343-025X)

Júlia Parreiras Drumond de Moraes<sup>22</sup> MD (Moraes JPD, juliadrumond\_@hotmail.com; 0000-0002-9538-6828)

Juliana Machado Rugolo<sup>4</sup> B.Sc (Machado-Rugolo J, jr.machado@unesp.br; 0000-0003-3984-4959)

Karen Brasil Ruschel<sup>17,24</sup> PhD (Ruschel KB, karenbruschel@gmail.com; 0000-0002-6362-1889)

Karina Paula Medeiros Prado Martins<sup>21,24</sup> MD, MSc (Martins KPM, kkpmp Prado2@gmail.com; 0000-0002-8313-7429)

Luanna Silva Monteiro Menezes<sup>25,26</sup> MD (Menezes LSM, luannasmonteiro@gmail.com; 0000-0002-6621-3338)

Luciana Siuves Ferreira Couto<sup>25</sup> (Couto LSF, lucianasiuves@gmail.com; 0000-0002-7948-222X)

Luís César de Castro<sup>28</sup> PhD (Castro LC, pharmlucamsc@gmail.com; 0000-0003-2379-0167)

Luiz Antônio Nasi<sup>27</sup> MD, PhD (Nasi LA, Inasi@terra.com.br; 0000-0002-7069-5827)

Máderson Alvares de Souza Cabral<sup>21</sup> MD (Cabral MAS, maderonalvares@hotmail.com; 0000-0001-8556-1998)

Maiara Anschau Floriani<sup>27</sup> MSc (Floriani MA, maiara.floriani@hmv.org.br; 0000-0002-2981-9445)

Maíra Dias Souza<sup>26</sup> MD (Souza MD, mairadiassouza@gmail.com; 0000-0003-3546-4000)

Maira Viana Rego Souza e Silva<sup>1</sup> MD (Souza-Silva MVR, mairavsouza@gmail.com; 0000-0003-2079-7291)

Marcelo Carneiro<sup>29</sup> MD, PhD (Carneiro M, marceloc@unisc.br; 0000-0003-3603-1987)

Mariana Frizzo de Godoy<sup>23</sup> MD (Godoy MF, mfdegodoy@gmail.com; 0000-0002-6631-8826)

Maria Aparecida Camargos Bicalho<sup>10</sup> MD, PhD (Bicalho MAC, macbicalho@gmail.com; 0000-0001-6298-9377)

Maria Clara Pontello Barbosa Lima<sup>30</sup> (Lima MCPB, mariaclarapontellobl@gmail.com; 0000-0003-0461-2787)

Matheus Carvalho Alves Nogueira<sup>31</sup> MD (Nogueira MCA,  
mathnogueira42@gmail.com; 0000-0002-0241-9046)

Matheus Fernandes Lopes Martins<sup>32</sup> (Martins MFL,  
matheus\_flm@hotmail.com)

Milton Henriques Guimarães-Júnior<sup>32</sup> MD, MSc (Guimarães Júnior MH,  
miltonhenriques@yahoo.com.br; 0000-0002-2127-8015)

Natália da Cunha Severino Sampaio<sup>33</sup> BSc (Sampaio NCS,  
natsamster@gmail.com; 0000-0002-5799-8006)

Neimy Ramos de Oliveira<sup>33</sup> MD (Oliveira NR, neimyramos@gmail.com; 0000-  
0001-5408-9459)

Patricia Klarmann Ziegelmann<sup>24,34</sup> PhD (Ziegelmann PK,  
patriciakz99@gmail.com; 0000-0002-2851-2011)

Pedro Guido Soares Andrade<sup>35</sup> MD (Andrade PGS, peuguido@icloud.com;  
0000-0002-4511-5149)

Pedro Ledic Assaf<sup>36</sup> MD (Assaf PL, pedro.ledic@hmdcc.com.br; 0000-0002-  
8419-5719)

Petrônio José de Lima Martelli<sup>20</sup> MSc, PhD (Martelli PJL,  
petroniocarla@uol.com.br; 0000-0001-6920-6435)

Polianna Delfino Pereira<sup>1,24</sup> MSc, PhD (Delfino-Pereira P,  
polidelfino@yahoo.com.br; 0000-0003-2406-6576)

Raphael Castro Martins<sup>34</sup> (Martins RC, rapahaelcm@gmail.com; 0000-0003-  
2167-3645)

Rochele Mosmann Menezes<sup>29</sup> MD (Menezes RM, rochelemenezes@unisc.br;  
0000-0002-1548-1607)

Saionara Cristina Francisco<sup>36</sup> MSc (Francisco SC, saionaracf@gmail.com; 0000-0002-9655-6294)

Silvia Ferreira Araújo<sup>35</sup> MD (Araújo SF, silviaferreiragastro@gmail.com; 0000-0003-4782-5440)

Talita Fischer Oliveira<sup>26</sup> MD (Oliveira TF, talitafischeroliveira@gmail.com; 0000-0002-4614-3109)

Thainara Conceição de Oliveira<sup>18</sup> B.Sc (Oliveira TC, thainarastaehler@hotmail.com; 0000-0002-1248-2305)

Thaís Lorena Souza Sales<sup>24,37</sup> MSc (Sales TLS, thaislorennass30@yahoo.com.br; 0000-0002-1571-3850)

Yuri Carlotto Ramires<sup>28</sup> MD (Ramires YC, yuri.ramires@gmail.com; 0000-0002-0730-8716)

Milena Soriano Marcolino<sup>1,21,24,38</sup> MD, MSc, PhD (Marcolino MS, milenamarc@gmail.com; 0000-0003-4278-3771)

## **Affiliations**

<sup>1</sup>Department of Internal Medicine, Medical School, Universidade Federal de Minas Gerais. Av. Professor Alfredo Balena, 190, Belo Horizonte, Brazil.

<sup>2</sup>Department of Medicine, Universidade Federal de Lavras. Aqueanta Sol, Lavras, Brazil.

<sup>3</sup>Department of Statistics, Universidade Federal de Minas Gerais. Av. Presidente Antônio Carlos, 6627, Belo Horizonte, Brazil.

<sup>4</sup>Botucatu Medical School, Universidade Estadual Paulista "Júlio de Mesquita Filho". Av. Prof. Mário Rubens Guimarães Montenegro, Botucatu, Brazil.

<sup>5</sup>Hospital Universitário de Santa Maria. Av. Roraima, 1000, Santa Maria, Brazil.

<sup>6</sup>Hospital São João de Deus. R. do Cobre, 800, Divinópolis, Brazil.

<sup>7</sup>Hospital Regional Antônio Dias. R. Maj. Gote, 1231, Patos de Minas, Brazil.

<sup>8</sup>Hospital Nossa Senhora da Conceição and Hospital Cristo Redentor. Av. Francisco Trein, 326, Porto Alegre, Brazil.

<sup>9</sup>Hospital Risoleta Tolentino Neves. R. das Gabirobas, 01, Belo Horizonte, Brazil.

<sup>10</sup>Hospital Júlia Kubitschek. Av. Professor Alfredo Balena, 190, Belo Horizonte, Brazil.

<sup>11</sup>Hospital Santo Antônio. Praça Dr. Márcio Carvalho Lopes Filho, 501, Curvelo, Brazil.

<sup>12</sup>Hospital Santa Rosália. R. do Cruzeiro, 01, Teófilo Otoni, Brazil.

<sup>13</sup>Mucuri Medical School, Universidade Federal dos Vales do Jequitinhonha e Mucuri. R. Cruzeiro, 01, Teófilo Otoni, Brazil.

<sup>14</sup>Hospital João XXIII. Av. Professor Alfredo Balena, 400, Belo Horizonte, Brazil.

<sup>15</sup>Department of Pediatrics, Medical School, Universidade Federal de Minas Gerais. Av. Professor Alfredo Balena, 190, Belo Horizonte, Brazil.

<sup>16</sup>Hospital UNIMED BH. Av. do Contorno, 3097, Belo Horizonte, Brazil.

<sup>17</sup>Hospital Mãe de Deus. R. José de Alencar, 286, Porto Alegre, Brazil.

<sup>18</sup>Hospital Universitário Canoas. Av. Farroupilha, 8001, Canoas, Brazil.

<sup>19</sup>Hospital SOS Córdio. Rodovia, SC-401, 121, Florianópolis, Brazil.

<sup>20</sup>Hospital das Clínicas da Universidade Federal de Pernambuco. Av. Prof. Moraes Rego, 1235, Recife, Brazil.

<sup>21</sup>Medical School and University Hospital, Universidade Federal de Minas Gerais. Avenida Professor Alfredo Balena, 190, Belo Horizonte, Brazil.

<sup>22</sup>Hospital Universitário Ciências Médicas. R. dos Aimorés, 2896, Belo Horizonte, Brazil.

<sup>23</sup>Hospital São Lucas da PUCRS. Av. Ipiranga, 6690, Porto Alegre, Brazil.

<sup>24</sup>Institute for Health Technology Assessment (IATS/ CNPq). R. Ramiro Barcelos, 2359, Porto Alegre, Brazil.

<sup>25</sup>Hospital Luxemburgo. R. Gentios, 1350, Belo Horizonte, Brazil.

<sup>26</sup>Hospital Metropolitano Odilon Behrens. R. Formiga, 50, Belo Horizonte, Brazil.

<sup>27</sup>Hospital Moinhos de Vento. R. Ramiro Barcelos, 910, Porto Alegre, Brazil.

<sup>28</sup>Hospital Bruno Born. Av. Benjamin Constant, 881, Lajeado, Brazil.

<sup>29</sup>Hospital Santa Cruz. R. Fernando Abott, 174, Santa Cruz do Sul, Brazil.

<sup>30</sup>Medical School, Universidade Federal de Ouro Preto. R. Diogo de Vasconcelos, 122, Ouro Preto, Brazil.

<sup>31</sup>Hospitais da Rede Mater Dei. Av. do Contorno, 9000, Belo Horizonte, Brazil.

<sup>32</sup>Hospital Márcio Cunha. Av. Kiyoshi Tsunawaki, 48, Ipatinga, Brazil.

<sup>33</sup>Hospital Eduardo de Menezes. R. Dr. Cristiano Rezende, 2213, Belo Horizonte, Brazil.

<sup>34</sup>Hospital Tacchini. R. Dr. José Mário Mônaco, 358, Bento Gonçalves, Brazil.

<sup>35</sup>Hospital Semper. Alameda Ezequiel Dias, 389, Belo Horizonte, Brazil.

<sup>36</sup>Hospital Metropolitano Doutor Célio de Castro. R. Dona Luiza, 311, Belo Horizonte, Brazil.

<sup>37</sup>Universidade Federal de São João del-Rei. R. Sebastião Gonçalves Coelho, 400, Divinópolis, Brazil.



<sup>38</sup>Telehealth Center, University Hospital, Universidade Federal de Minas Gerais. Av. Professor Alfredo Balena, 110, Belo Horizonte, Brazil.

**Correspondence to:** Flávio de Azevedo Figueiredo

Rua Tomas Antonio Gonzaga, 277

Centro - Lavras – MG. Brazil.

CEP 37200-134

## ABSTRACT

**Background:** Acute kidney injury (AKI) is frequently associated with COVID-19 and the need for kidney replacement therapy (KRT) is considered an indicator of disease severity. This study aimed to develop a prognostic score for predicting the need for KRT in hospitalized COVID-19 patients.

**Methods:** This study is part of the multicentre cohort, the Brazilian COVID-19 Registry. A total of 5,212 adult COVID-19 patients were included between March/2020 and September/2020. We evaluated four categories of predictor variables: (1) demographic data; (2) comorbidities and conditions at admission; (3) laboratory exams within 24 h; and (4) the need for mechanical ventilation at any time during hospitalization. Variable selection was performed using generalized additive models (GAM) and least absolute shrinkage and selection operator (LASSO) regression was used for score derivation. The accuracy was assessed using the area under the receiver operating characteristic curve (AUC-ROC). Risk groups were proposed based on predicted probabilities: non-high (up to 14.9%), high (15.0 – 49.9%), and very high risk ( $\geq 50.0\%$ ).

**Results:** The median age of the model-derivation cohort was 59 (IQR 47-70) years, 54.5% were men, 34.3% required ICU admission, 20.9% evolved with AKI, 9.3% required KRT, and 15.1% died during hospitalization. The validation cohort had similar age, sex, ICU admission, AKI, required KRT distribution and in-hospital mortality. Thirty-two variables were tested and four important predictors of the need for KRT during hospitalization were identified using GAM: need for mechanical ventilation, male gender, higher creatinine at

admission, and diabetes. The MMCD score had excellent discrimination in derivation (AUROC = 0.929; 95% CI 0.918–0.939) and validation (AUROC = 0.927; 95% CI 0.911–0.941) cohorts an good overall performance in both cohorts (Brier score: 0.057 and 0.056, respectively). The score is implemented in a freely available online risk calculator (<https://www.mmcdscore.com/>).

**Conclusion:** The use of the MMCD score to predict the need for KRT may assist healthcare workers in identifying hospitalized COVID-19 patients who may require more intensive monitoring, and can be useful for resource allocation.

**Keywords:** Acute kidney injury; COVID-19; kidney replacement therapy; score; risk factors; risk prediction.

## **BACKGROUND**

Coronavirus disease 19 (COVID-19) course is mild in most cases, but it can be severe and critical, with multiple organ dysfunction, septic shock and death [1]. Kidney disease among patients with COVID-19 can manifest as acute kidney injury (AKI), hematuria, or proteinuria, and it has been associated with an increased risk of mortality [2].

The incidence of AKI among hospitalized patients with COVID-19 has shown to be variable, depending upon the severity of the disease and whether they are outpatient, in the ward or intensive care unit (ICU) environment. A recent systematic review, which included 30 studies and 18,043 patients with COVID-19, observed an overall incidence of AKI of 9.2% (95% confidence interval [CI] 4.6–13.9%), and 32.6% (95% CI 8.5–56.6%) in the ICU [3].

Another systematic review from the beginning of the pandemic included 79 studies and 49,692 patients, and observed a significant variation in the incidence of AKI and kidney replacement therapy (KRT) and the risk of death in patients who develop AKI depending on the continent. The incidence of AKI, KRT requirement and death in patients with AKI was 4.3%, 1.4% and 33.3% in Asia, 11.6%, 5.7% and 29.4% in Europe and 22.6%, 4.0% and 7.4% in North America, respectively [4]. There is a lack of studies from large cohorts in Latin America, which was severely hit by the pandemic.

Previous studies have explored the factors associated with AKI development in COVID-19 patients, including advanced age; black race; underlying medical conditions such as diabetes mellitus, cardiovascular disease, chronic kidney disease and hypertension; COVID-19 severity; use of vasopressor medications and mechanical ventilation requirement [4, 5]. However, most studies are limited to univariate analysis or have small sample sizes and there is a lack of studies analyzing independent risk factors for KRT requirement.


A risk score to predict KRT requirement during hospitalization, using clinical and laboratory data upon hospital presentation may be very useful aiming at a better allocation of health resources. However, there is a lack of evidence in this context. Fang *et al* [6] used a score created before the pandemic (UCSD-Mayo risk score) and analysed its efficiency in predicting hospital-acquired AKI in patients with COVID-19, but the performance of the score in patients in ICUs or under mechanical ventilation was not satisfactory.

Therefore, we aimed to assess the incidence of AKI and KRT requirement in COVID-19 in-hospital patients, as well as to develop and validate a score to predict the risk of the need for KRT.

## **METHODOLOGY**

This cohort study is part of the Brazilian COVID-19 Registry, which included consecutive patients  $\geq 18$  years-old, hospitalized with COVID-19 confirmed by laboratory test according to WHO criteria, admitted from March 2020 to September 2020 in 37 Brazilian hospitals, located in 17 cities, from five Brazilian states. For the present analysis, patients with chronic kidney disease stage 5 in dialysis previous to COVID-19, admitted with another diagnosis and developed COVID-19 after admission and/or those who were transferred to other hospitals (not part of the multicenter study) during hospitalization were not included. Two hospitals that did not comply with the study protocol were excluded (Figure 1).

Model development, validation and reporting followed guidance from the Transparent Reporting of a Multivariable Prediction Model for Individual Prediction or Diagnosis (TRIPOD) checklist (Table S1) and Prediction model Risk Of Bias Assessment Tool (PROBAST) [7, 8].



**Figure 1.** Flowchart of COVID-19 patients included in the study.

### *Data collection and outcome*

Data were extracted from the medical records in participant hospitals, including patient demographic information, comorbidities, laboratory results, treatments (including KRT) and outcomes. Data were collected by using a prespecified case report form applying Research Electronic Data Capture (REDCap) tools. Variables used in the risk score were obtained at admission, with the exception of the need for mechanical ventilation, which may have occurred at any time during the hospital stay, except in those patients in which it was initiated after KRT requirement.

The primary endpoint was KRT requirement. Secondary endpoints were the incidence of AKI and mortality in patients who required KRT.

### *Statistical analysis*

In the descriptive analyses, categorical variables were described as absolute and relative frequency, and continuous variables by median and quartiles.

The dataset was split into development and validation, according to the date of hospital admission, using July 21, 2020 as the temporal cut (temporal validation).

All analyses were performed using R software version 4.0.2, with the mgcv, finalfit, mice, glmnet, pROC, rms, rmda, and psfmi packages. A  $p$ -value $<0.05$  was considered statistically significant for all analyses and 95% confidence intervals were reported.

#### *Missing data*

Predictors were imputed if they had up to two thirds of complete values. Variables with a higher proportion of missing values than that were not included in the analysis. After analysing missing data patterns, multiple imputation with chained equations (MICE) was used to handle missing values on candidate variables, considering missing at random. Outcomes were not imputed. Predictive mean matching (PMM) method was used for imputation of continuous predictors and polytomous regression for categorical variables. The results of ten imputed datasets, each with ten iterations, were then combined, following Rubin's rules [9].

#### *Development of the risk score model*

Predictor selection was based on clinical reasoning and literature review before modeling, as recommended [8]. The development cohort included patients admitted before July 21, 2020.

Variable selection was performed using generalized additive models (GAM), evaluating the relationships between KRT requirement and continuous (through penalized thin plate splines) and categorical (as linear components) predictors and calculating D1- (multivariate Wald test) and D2- statistic (pools test statistics from the repeated analyses).

As our aim was to develop a score for easy application at bedside, continuous variables were categorized on cut-off points, based on evidence from an established score for sepsis [8, 10].

Subsequently, least absolute shrinkage and selection operator (LASSO) logistic regression was used to derive the score by scaling the (L1 penalized) shrunk coefficients (Table S2). Ten-fold cross-validation methods based on mean squared error criterion were used to choose the penalty parameter  $\lambda$  in LASSO.

Lastly, risk groups were proposed based on predicted probabilities: **non-high** (up to 14.9%), **high** (15.0 – 49.9%), and **very high** risk ( $\geq 50.0\%$ ).

The specific risks can be easily assessed using the developed MMCD risk score web-based calculator (<https://www.mmcdscore.com>), which is freely available to the public.

### *Model validation*

Patients who were admitted in participant hospitals from July 22, 2020 to September, 2020 were included as the external (temporal) validation cohort.

### *Performance measures*


To assess model calibration, predicted dialysis probabilities were plotted against the observed values. To assess model discrimination, the area



under the receiver operating characteristic curve (AUROC) was calculated, with the respective confidence interval (95% CI), obtained through 2000 bootstrap samples. Positive and negative predictive values of the derived risk groups were also calculated. The Brier score was used to assess the overall performance [11].

## RESULTS

The derivation cohort included 3,680 COVID-19 patients admitted to the 35 participating hospitals, from March 1, 2020 to July 21, 2020. Those patients were from 159 cities in Brazil (Figure 2). The median age was 59 (IQR 47-70) years, 54.5% were men, 20.9% evolved with AKI, 9.3% required KRT, and 15.1% died during hospitalization. Patient demographics, underlying medical conditions, clinical characteristics, and laboratory values upon hospital presentation for the derivation and validation cohorts are displayed in Table 1.



**Figure 2.** City of residence of patients from (a) the development and (b) the validation cohorts.

Among the patients in the derivation cohort, 1,261 (34.3%) required ICU admission. Of those, 16.7% developed AKI and 9.1% required KRT, with a mortality rate of 64.7% and 76.7%, respectively.

**Table 1.** Demographic and clinical characteristics for derivation and validation cohorts of patients admitted to participant hospitals with COVID-19 (n=5,112).

Label	Derivation cohort		Validation cohort	
Characteristic	N = 3,680 <sup>a</sup>	Non missing cases (%)	N = 1,532 <sup>a</sup>	Non missing cases (%)
Age (years)	59.0 (47.0, 70.0)	3,680 (100%)	62.0 (48.0, 72.0)	1,532 (100%)
Sex at birth		3,680 (100%)		1,532 (100%)
Men	2,004 (54.5%)		869 (56.7%)	
<b>Comorbidities</b>				
Hypertension	1,977 (53.7%)	3,680 (100%)	822 (53.7%)	1,532 (100%)
Coronary artery disease	180 (4.9%)	3,680 (100%)	76 (5.0%)	1,532 (100%)
Heart failure	224 (6.1%)	3,680 (100%)	74 (4.8%)	1,532 (100%)
Atrial fibrillation/flutter	105 (2.9%)	3,680 (100%)	47 (3.1%)	1,532 (100%)
Stroke	106 (2.9%)	3,680 (100%)	53 (3.5%)	1,532 (100%)
COPD	198 (5.4%)	3,680 (100%)	94 (6.1%)	1,532 (100%)
Diabetes mellitus	1,009 (27.4%)	3,680 (100%)	453 (29.6%)	1,532 (100%)
Obesity (BMI ≥ 30kg/m <sup>2</sup> )	712 (19.3%)	3,680 (100%)	273 (17.8%)	1,532 (100%)
Cirrhosis	17 (0.5%)	3,680 (100%)	9 (0.6%)	1,532 (100%)

Cancer	170 (4.6%)	3,680 (100%)	75 (4.9%)	1,532 (100%)
Number of Comorbidities <sup>b</sup>		3,680 (100%)		1,532 (100%)
0	1,128 (30.7%)		434 (28.3%)	
1	1,107 (30.1%)		501 (32.7%)	
2	923 (25.1%)		392 (25.6%)	
3	384 (10.4%)		149 (9.7%)	
≥ 4	138 (3.8%)		56 (3.7%)	
<b>Clinical assessment at admission</b>				
SF ratio	433.3 (339.3, 452.4)	3,582 (97%)	433.3 (342.9, 452.4)	1,506 (98%)
Heart rate (bpm)	88.0 (78.0, 100.0)	3,545 (96%)	87.0 (77.0, 100.0)	1,489 (97%)
Respiratory rate (irpm)	20.0 (18.0, 24.0)	3,043 (83%)	20.0 (18.0, 24.0)	1,255 (82%)
Glasgow coma scale	15.0 (15.0, 15.0)	3,460 (94%)	15.0 (15.0, 15.0)	1,441 (94%)
Systolic blood pressure		3,524 (96%)		1,489 (97%)
≥ 90 (mm Hg)	3,338 (94.7%)		1,413 (94.9%)	
< 90 (mm Hg)	45 (1.3%)		23 (1.5%)	
Inotrope requirement	141 (4.0%)		53 (3.6%)	
Diastolic blood pressure		3,489 (95%)		1,481 (97%)
> 60 (mm Hg)	2,911 (83.4%)		1,236 (83.5%)	
≤ 60 (mm Hg)	437 (12.5%)		192 (13.0%)	
Inotrope requirement	141 (4.0%)		53 (3.6%)	

Mechanical ventilation at admission	183 (5.0%)	3,676 (100%)	63 (4.1%)	1,530 (100%)
Mechanical ventilation after admission	774 (21.0%)	3,680 (100%)	276 (18.0%)	1,532 (100%)
<b>Laboratory parameters</b>				
Hemoglobin (g/L)	13.4 (12.2, 14.5)	3,534 (96%)	13.4 (12.1, 14.6)	1,491 (97%)
Platelet count (10 <sup>9</sup> /L)	193,500.0 (152,000.0, 252,000.0)	3,497 (95%)	203,000.0 (156,000.0, 263,850.0)	1,478 (96%)
Neutrophils-to-lymphocytes ratio	4.4 (2.7, 7.4)	3,447 (94%)	4.9 (2.9, 8.2)	1,437 (94%)
Lactate value	1.4 (1.0, 1.8)	2,420 (66%)	1.5 (1.1, 2.0)	999 (65%)
C reactive protein (mg/L)	71.0 (34.0, 134.6)	3,178 (86%)	73.5 (35.5, 134.8)	1,311 (86%)
Urea (mg/dL)	33.0 (24.0, 47.0)	3,310 (90%)	37.0 (27.2, 52.8)	1,376 (90%)
Creatinine (mg/dL)	0.9 (0.7, 1.2)	3,417 (93%)	1.0 (0.8, 1.2)	1,434 (94%)
Sodium (mmol/L)	137.0 (135.0, 140.0)	3,215 (87%)	137.0 (134.9, 140.0)	1,356 (89%)
Bicarbonate (mEq/L)	23.2 (21.2, 25.2)	2,957 (80%)	23.0 (21.0, 25.0)	1,217 (79%)
pH	7.4 (7.4, 7.5)	2,968 (81%)	7.4 (7.4, 7.5)	1,217 (79%)
Arterial pO <sub>2</sub>	75.0 (63.8, 94.0)	2,927 (80%)	74.3 (63.0, 93.7)	1,203 (79%)
Arterial pCO <sub>2</sub>	35.0 (31.9, 39.0)	2,940 (80%)	34.0 (30.9, 38.0)	1,205 (79%)
Dialysis	343 (9.3%)	3,680 (100%)	128 (8.4%)	1,532 (100%)
In hospital mortality	554 (15.1%)	3,679 (100%)	229 (14.9%)	1,532 (100%)

<sup>a</sup>Statistics presented: n (%); Median (IQR) COPD: chronic obstructive pulmonary disease, SF ratio: SpO<sub>2</sub>/FiO<sub>2</sub> ratio, BMI: body mass index. <sup>b</sup>Comorbidities included: hypertension, diabetes mellitus, obesity, coronary artery disease, heart failure, atrial fibrillation or flutter, cirrhosis, chronic obstructive pulmonary disease, cancer, and previous stroke.

## Model development

Sixty-three potential risk predictor variables collected at hospital admission were identified (Table S3). Of those, 20 were excluded for high collinearity and 11 for high number of missings variables. Consequently, 32 variables were tested.

Four important predictors of the need for KRT during hospitalization were identified using GAM: need for mechanical ventilation, male sex, higher creatinine at admission, and diabetes. Continuous selected predictors were categorized for LASSO logistic regression due to the need for a bedside use score (Table 2). The sum of the prediction scores ranges between 0 and 23, with a high score indicating higher risk of dialysis. Three risk groups were defined based on predicted probabilities of KRT requirement: non high risk (0-10 score, observed KRT rate 0.4%), high risk (11-14 score, 32.8%) and very high risk (15-23 score, 68.0%), as shown in Table 3.

**Table 2.** MMCD score for in-hospital KRT requirement in COVID-19 patients

Variable		MMCD Score
<b>M</b>	<b>Mechanical ventilation anytime during hospital stay<sup>a</sup></b>	
	No	0
	Yes	11
<b>M</b>	<b>Sex</b>	
	Women	0
	Men	1
<b>C</b>	<b>Creatinine (mg/dL) upon hospital presentation</b>	
	< 1.2	0
	1.2 - 2.0	1
	2.0 - 3.5	2
	3.5 - 5.0	4
	≥ 5.0	10
<b>D</b>	<b>Diabetes mellitus</b>	
	No	0
	Yes	1

<sup>a</sup> Except in those cases the dialysis preceded mechanical ventilation.

**Table 3.** Predicted probability of dialysis and dialysis rates for MMCD score risk groups

Risk Groups	Derivation cohort			Validation cohort	
Risk Group	Predicted probability	No. of patients	No. of dialysis cases	No. of patients	No. of dialysis cases
Non high risk (0-10)	0 - 14.9%	2,719	10 (0.4%)	1,192	8 (0.7%)
High (11-14)	15 - 49.9%	911	299 (32.8%)	310	108 (34.8%)
Very high (15-23)	≥ 50%	50	34 (68%)	30	12 (40%)
Overall	-	3,680	343 (9.3%)	1,532	128 (8.4%)

Discrimination and model overall performance in derivation and validation cohorts for GAM, LASSO and MMCD score are shown in Table 4. Within the derivation cohort, the MMCD risk score showed excellent discrimination (AUROC = 0.929; 95% CI 0.918–0.939) a good overall performance (Brier score: 0.057) (figure 3a).

**Table 4.** Discrimination and model overall performance in derivation and validation cohorts


Models	Derivation cohort		Validation cohort	
Model	AUROC (95% CI)	Brier score	AUROC (95% CI)	Brier score
GAM	0.938 (0.926-0.947)	0.053	0.917 (0.893-0.937)	0.057
LASSO	0.929 (0.918-0.938)	0.057	0.929 (0.914-0.943)	0.055
MMCD score	0.929 (0.918-0.939)	0.057	0.927 (0.911-0.941)	0.056

#### *Model validation*

A total of 1,532 patients admitted between July 22, 2020 and September 31, 2020 were included in the validation cohort. The median age was 62 (IQR 48-72) years; 56.7% were male, 19.8% evolved with AKI, 8.4% required KRT, and 14.9% died during hospitalization.

In the validation cohort, 515 (33.6%) required ICU admission. Of those, 14.6% developed AKI and 8.1% required KRT, with a mortality rate of 65.5% and 82.3%, respectively.

The MMCD Score had an AUROC of 0.927 (95% CI 0.911-0.941), calibration and performance were good (slope=0.849, Brier score=0.056 intercept=-0.186), under the validation cohort (Figure 3b, Figure S1 and Figure S2).



**Figure 3.** Derivation (a) and Validation (b) cohort ROC curve

## DISCUSSION

This study included more than 5,000 patients hospitalized with a diagnosis of COVID-19 in the different hospitals included in the Brazilian COVID-19 Registry, a robust cohort of patients with a comprehensive dataset. One in every five patients evolved with AKI and 9.3% required KRT. Among the analyzed predictors, four variables were related to progression to AKI and KRT requirement, including: the need for mechanical ventilation, sex, creatinine upon hospital presentation and diabetes mellitus.

Renal involvement in COVID-19 infection is complex and probably occurs due to several factors. Direct renal injury by the SARS-CoV-2 to the renal endothelium, tubular epithelium and podocytes has been described, infecting the cell through angiotensin converting enzyme 2 receptors, which



are abundantly present in the renal tissue [12]. In addition to this mechanism, there are numerous factors worsening the kidney injury, such as: cytokine storm with the release of several interleukins and cytokines, mainly interleukin-6 (IL-6) [3]; cardiorenal syndrome, caused by right ventricular dysfunction secondary to pulmonary infection; hypercoagulable state with a coronary lesion, left ventricular dysfunction and consequent low renal output, worsened by hypovolemia; and release of nephrotoxic substances such as creatine phosphokinase secondary to rhabdomyolysis [2].

The need for mechanical ventilation at any time during hospitalization was an important predictor of progression to AKI and the need for KRT, being the variable with the highest points in the risk score. Scoring mechanical ventilation only changed patients' category to “high risk” for evolving to AKI and KRT requirement. Another study from the USA (United States of America) with 5,449 patients, the need for mechanical ventilation was a significant risk factor for AKI and KRT requirement [5]. This finding confirms findings from studies carried out in other countries, such as a study in the USA from the beginning of the pandemic, in which mechanical ventilation was the strongest predictor for AKI (OR 10.7 [95% CI 6.81–16.70]) [5]. In another study from the United Kingdom, which included ICU patients, mechanical ventilation was also the strongest predictor, associated with a four-fold risk of progression of AKI in COVID-19 patients [13]. Study in patients hospitalized with COVID-19 in the city of Wuhan, China, with a significant difference in the need for mechanical ventilation between patients with and without AKI (54.4% vs. 13.7%) [14]. Finally, a study developed in Brazil with patients hospitalized in a single-center with COVID-19 that described the need for mechanical ventilation

among patients without AKI, with AKI and with AKI associated with KRT needed were 17.0%, 69,3% and 100% [15]. There is a close relationship between alveolar and tubular damage (lung-kidney axis) in acute respiratory distress syndrome (ARDS), often progressing to different degrees of AKI [16]. The relationship between mechanical ventilation (MV) and AKI has been widely recognized before the COVID-19 pandemic. Animal models suggest a causal relationship between MV and AKI through a reduction in renal blood flow, apparently by an impairment in intrarenal microcirculation due to hypoxemia and hypercapnia, as well as a drop in cardiac output due to changes in intrathoracic pressure with MV [17]. Additionally, the extrinsic positive end expiratory pressure (PEEP) seems to be associated with a redistribution of intra-renal blood flow, and “biotrauma” may be another cause. This is a complex and not fully understood mechanism, in which inflammatory mediators are released by ventilated lungs into the systemic circulation [18].

Therefore, AKI in patients who require mechanical ventilation seems to be multifactorial, and it is difficult to define the specific role that each mechanism plays in the pathogenesis of AKI. They are usually observed simultaneously in critically ill patients, which limits the possibility to develop preventive strategies [19].

In studies published by Chan L et al (n=3,993) [20] and Fisher M et al (n=3,345) [21] with hospitalized patients with COVID-19 in the USA, male sex was considered an independent predictor of progression to AKI and KRT requirement. In our study, the male sex was a risk predictor variable for the evolution of AKI and the need for KRT, being included in the risk score. Male sex has been previously observed to be associated with other adverse

outcomes in COVID-19 patients. In a recent meta-analysis with over three million COVID-19 cases, the authors observed no difference in the proportion of men and women who developed COVID-19, but men had almost three times the odds of requiring ICU admission (OR = 2.84; 95% CI = 2.06, 3.92) and higher odds of death (OR = 1.39; 95% CI = 1.31, 1.47) compared to women [22].

Creatinine levels upon hospital presentation may be evidence of previous chronic kidney disease or an early manifestation of AKI caused by COVID-19 infection. Chronic kidney disease is a global health problem and a silent disease [23]. Serum creatinine levels were categorized according to the Sequential Organ Failure Assessment Score (SOFA) [10] to comply with TRIPOD guidelines, which advises not to use a data-driven method, to avoid model overfitting [8]. Our finding is consistent with a recent systematic review and meta-analysis with 22 studies (n=17,391), which observed an increased incidence of AKI in COVID-19 patients hospitalized in the USA who had abnormal baseline serum creatinine levels due to pre-existing chronic kidney disease [24]. Hansrivijit P et al [25] in their meta-analysis described abnormal basal serum creatinine levels as predictors of progression to AKI.

The association between diabetes mellitus and renal dysfunction is well known, in the form of diabetic nephropathy, as a result not only of intrarenal atherosclerosis and arteriosclerosis, but also non-inflammatory glomerular damage [26, 27]. Among the predictor variables analyzed in this study, diabetes proved to be a predictor of risk of progression to AKI and KRT requirement in patients hospitalized with COVID-19. A meta-analysis published in 2020 with 26 studies (n=5,497) evaluated the incidence of AKI in

patients with COVID-19 and showed that diabetes was a predisposing factor for progression to AKI [25].

Meta-analyses showed that the association of patients diagnosed with COVID-19 who developed AKI had higher mortality, which was enhanced by the need for KRT [4, 28]. In Brazil, a country severely hit by the pandemic, there is lack of evidence on the association among AKI, need for KRT, mortality and COVID-19. The scarce existing studies are based in small databases. A study published with 200 ICU-patients showed a high incidence of AKI (about 50%) and 17% of patients requiring KRT, with significantly higher mortality in patients with AKI and needing KRT, in contrast to patients without AKI and KRT requirement [15]. In our study, the incidence of AKI and need for KRT in ICU-patients were lower (about 16% and 9%, respectively), although with higher in-hospital death in this group, similarly to finds in this article.

The MMCD model retrieved an AUROC of 0.96, which was classified as a excellent discrimination. An American study (n=2,256) developed prediction models of KRT using machine learning techniques, comparing L1-penalized logistic regression (logistic L1), elastic-net logistic regression (logistic EN) and gradient boosted trees (GBT). Logistic L1 had the best accuracy in the validation cohort. However, the discrimination results were inferior than the one observed in the present analysis (0.847 [95% CI, 0.772-0.936]) and the study has several limitations: many risk predictor variables, hindering the applicability of the score and high incidence of missing variables [29].

## **Strengths and limitations**

Our study used a large patients database to develop a risk score to predict the need for KRT in patients admitted with COVID-19. A major strength of the MMCD score is its simplicity; the use of objective parameters, which may reduce the variability; and easy availability, even in under-resourced settings. Then, the MMCD score may help clinicians to make a prompt and reasonable decision to optimize the management of COVID-19 patients with AKI and potentially reduce mortality. Additionally, our article strictly followed the TRIPOD recommendations [8].

This study has limitations. Indication and timing of initiation of the KRT may differ according to institutional protocols, and we did not collect information on patients who did not perform dialysis due to limited resources. Still, this has not affected the accuracy of the score. Additionally, as any other score, MMCD may not be directly generalized to populations from other countries. Furthermore, it was not possible to use the KDIGO (Kidney Disease: Improving Global Outcomes) classification for AKI due to the lack of data on previous serum creatinine of patients admitted to participating hospitals. Instead, we used the SOFA score, which has been widely used for ICU patients for years, and it is currently recommended to assess organ dysfunction in patients suspected of sepsis [30]. In patients with abnormal serum creatinine levels, it was not possible to define the causal factor (previous chronic kidney disease vs. COVID-19) due to the lack of data prior to the patient's hospitalization.

## **Possible applications**

Using predictors available at baseline and within the first hours of the admission, we could objectively predict the probability of KRT of a COVID-19 patient with AKI. With an accurate prediction, it may help to organize resource allocation to patients who are at the highest risk of KRT requirement [29], in addition to selecting patients who may benefit from renal protection strategies, close assessment and follow-up by a nephrologist [31].

## **CONCLUSIONS**

In conclusion, we developed and validated a clinical prediction score named MMCD, to predict the need for KRT in COVID-19 patients. This score used a few predictors available at baseline and mechanical ventilation anytime during hospital admission, and retrieved a good accuracy. This could be an inexpensive tool to predict the need for KRT objectively and accurately. Additionally, it may be used to inform clinical decisions and the assignment to the appropriate level of care and treatment for COVID-19 patients with AKI.

## **List of abbreviations**

AKI: acute kidney injury

ARDS: acute respiratory distress syndrome

AUROC: area under the receiver operating characteristic

BMI: body mass index

BPM1: beats per minute

BPM2: breaths per minute

CI: confidence interval

COPD: chronic obstructive pulmonary disease

COVID-19: Coronavirus disease 19

GAM: generalized additive models

GBT: gradient boosted trees

ICU: intensive care unit

IL-6: interleukin-6

IQR: interquartile range

KDIGO: Kidney Disease: Improving Global Outcomes

KRT: kidney replacement therapy

LASSO: least absolute shrinkage and selection operator

MICE: multiple imputation with chained equations

MMCD: mechanical ventilation, male, creatinine, diabetes

MV: mechanical ventilation

pCO<sub>2</sub>: partial pressure of carbon dioxide

PEEP: positive end-expiratory pressure

PMM: Predictive mean matching

PO<sub>2</sub>: partial pressure of oxygen

PROBAST: Prediction model Risk Of Bias Assessment Tool

REDCap: Research Electronic Data Capture

SBP: systolic blood pressure

SF ratio: SpO<sub>2</sub>/FiO<sub>2</sub> ratio

SOFA: Sepsis-related Organ Failure Assessment

TRIPOD: Transparent Reporting of a Multivariable Prediction Model for

Individual Prediction or Diagnosis

USA: United States of America

## DECLARATIONS

### *Ethics approval and consent to participate*

This study was approved by Brazilian National Committee for Ethics in Research - CONEP (CAAE - Certificate of presentation of Ethical Appreciation: 30350820.5.1001.0008).

### *Consent for publication*

Informed consent was waived due to the pandemic situation and the study design, based on data collection from medical records only.

### *Availability of data and materials*

*Any additional data pertaining to this manuscript are available from the corresponding author upon reasonable request.*

### *Competing interests*

The authors declare that they have no competing interests. The sponsors had no role in study design; data collection, management, analysis, and interpretation; writing the manuscript; and deciding to submit it for publication.

### *Funding*

This study was supported in part by Minas Gerais State Agency for Research and Development (*Fundação de Amparo à Pesquisa do Estado de Minas Gerais - FAPEMIG*) [grant number APQ-00208-20] and National Institute of Science and Technology for Health Technology Assessment (*Instituto de Avaliação de Tecnologias em Saúde – IATS*)/ National Council for Scientific and Technological Development (*Conselho Nacional de Desenvolvimento Científico e Tecnológico - CNPq*) [grant number 465518/2014-1].



### *Authors' contributions*

Conception or design of the work: MSM and MCP. Data collection: AVS, AOM, ALBAS, AFG, BLF, BMG, CTCAS, CCRC, CAC, DVS, EFRM, EPAC, FA, FGA, FCA, FB, GGV, GFN, HCN, HD, HRV, HCG, JCA, JMC, JPDM, JMR, KBR, KPMPM, LSMM, LSFC, LCC, LAN, MASC, MAF, MDS, MVRSS, MC, MFG, MACB, MCPBL, MCAN, MFLM, MHGJ, NCSS, NRO, PKZ, PGSA, PLA, PJLM, PDP, RLRC, RCM, RMM, SCF, SFA, TFO, TCO, TLSS, YCR and MSM. Data analysis and interpretation: MSM, MCP, LEFR, RTS and FAF. Drafting the article: FAF, MSM, MCP, CSD and DP. Critical revision of the article: all authors. Final approval of the version to be published: all authors.

### *Acknowledgements*

We would like to thank the hospitals, which are part of this collaboration: Hospital das Clínicas da Faculdade de Medicina de Botucatu; Hospital Universitário de Santa Maria; Hospital São João de Deus; Hospital Regional Antônio Dias; Hospital Nossa Senhora da Conceição; Hospital Cristo Redentor; Hospital Risoleta Tolentino Neves; Hospital Júlia Kubitschek; Hospital Santo Antônio; Hospital Santa Rosália; Hospital João XXIII; Hospital UNIMED BH; Hospital Mãe de Deus; Hospital Universitário Canoas; Hospital SOS Córdio; Hospital das Clínicas da Universidade Federal de Pernambuco; Hospital das Clínicas da UFMG; Hospital Universitário Ciências Médicas; Hospital São Lucas da PUCRS; Hospital Luxemburgo; Hospital Metropolitano Odilon Behrens; Hospital Moinhos de Vento; Hospital Bruno Born; Hospital Santa Cruz; Hospitais da Rede Mater Dei; Hospital Márcio Cunha; Hospital Eduardo de Menezes; Hospital Tacchini; Hospital Semper and Hospital

Metropolitano Doutor Célio de Castro. We also thank all the clinical staff at those hospitals, who cared for the patients, and all students who helped with the data collection.

## REFERENCES

1. Wu Z, McGoogan JM (2020) Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China. *JAMA* 323:1239
2. Ronco C, Reis T, Husain-Syed F (2020) Management of acute kidney injury in patients with COVID-19. *The Lancet Respiratory Medicine* 8:738–742
3. dos Santos RP, Lordani TVA, Peres LAB, Carvalho AR da S (2021) Occurrence of acute kidney injury in adult patients hospitalized with COVID-19: A systematic review and meta-analysis. *Nefrología*.
4. Lin L, Wang X, Ren J, Sun Y, Yu R, Li K, Zheng L, Yang J (2020) Risk factors and prognosis for COVID-19-induced acute kidney injury: a meta-analysis. *BMJ Open* 10:e042573
5. Hirsch JS, Ng JH, Ross DW, et al (2020) Acute kidney injury in patients hospitalized with COVID-19. *Kidney International* 98:209–218
6. Fang Z, Gao C, Cai Y, et al (2021) A validation study of UCSD-Mayo risk score in predicting hospital-acquired acute kidney injury in COVID-19 patients. *Renal Failure* 43:1115–1123
7. Wolff RF, Moons KGM, Riley RD, Whiting PF, Westwood M, Collins GS, Reitsma JB, Kleijnen J, Mallett S (2019) PROBAST: A Tool to Assess the Risk of Bias and Applicability of Prediction Model Studies. *Annals of Internal Medicine* 170:51

8. Moons KGM, Altman DG, Reitsma JB, Ioannidis JPA, Macaskill P, Steyerberg EW, Vickers AJ, Ransohoff DF, Collins GS (2015) Transparent Reporting of a multivariable prediction model for Individual Prognosis Or Diagnosis (TRIPOD): Explanation and Elaboration. *Annals of Internal Medicine* 162:W1–W73
9. Rubin DB (2004) Multiple imputation for nonresponse in surveys.
10. Vincent J-L, de Mendonca A, Cantraine F, Moreno R, Takala J, Suter PM, Sprung CL, Colardyn F, Blecher S (1998) Use of the SOFA score to assess the incidence of organ dysfunction/failure in intensive care units. *Critical Care Medicine* 26:1793–1800
11. Rufibach K (2010) Use of Brier score to assess binary predictions. *Journal of Clinical Epidemiology* 63:938–939
12. Su H, Yang M, Wan C, et al (2020) Renal histopathological analysis of 26 postmortem findings of patients with COVID-19 in China. *Kidney International* 98:219–227
13. Lumlertgul N, Pirondini L, Cooney E, Kok W, Gregson J, Camporota L, Lane K, Leach R, Ostermann M (2021) Acute kidney injury prevalence, progression and long-term outcomes in critically ill patients with COVID-19: a cohort study. *Annals of Intensive Care* 11:123
14. Wang F, Ran L, Qian C, et al (2021) Epidemiology and Outcomes of Acute Kidney Injury in COVID-19 Patients with Acute Respiratory Distress Syndrome: A Multicenter Retrospective Study. *Blood Purification* 50:499–505
15. Doherty MP, Torres de Carvalho FR, Scherer PF, et al (2021) Acute Kidney Injury and Renal Replacement Therapy in Critically Ill COVID-19 Patients: Risk Factors and Outcomes: A Single-Center Experience in Brazil. *Blood Purification* 50:520–530

16. Panitchote A, Mehkri O, Hastings A, Hanane T, Demirjian S, Torbic H, Mireles-Cabodevila E, Krishnan S, Duggal A (2019) Factors associated with acute kidney injury in acute respiratory distress syndrome. *Annals of Intensive Care* 9:74
17. Zillig B, Schuler G, Truniger B (1978) Renal function and intrarenal hemodynamics in acutely hypoxic and hypercapnic rats. *Kidney International* 14:58–67
18. Kuiper J, Vaschetto R, Corte F, Plötz FB, Groeneveld AJ (2011) Bench-to-bedside review: Ventilation-induced renal injury through systemic mediator release - just theory or a causal relationship? *Critical Care* 15:228
19. Lombardi R, Nin N, Peñuelas O, et al (2017) Acute Kidney Injury in Mechanically Ventilated Patients: The Risk Factor Profile Depends on the Timing of Aki Onset. *Shock (Augusta, Ga)* 48:411–417
20. Chan L, Chaudhary K, Saha A, et al (2021) AKI in Hospitalized Patients with COVID-19. *Journal of the American Society of Nephrology* 32:151–160
21. Fisher M, Neugarten J, Bellin E, et al (2020) AKI in Hospitalized Patients with and without COVID-19: A Comparison Study. *Journal of the American Society of Nephrology* 31:2145–2157
22. Peckham H, de Gruijter NM, Raine C, Radziszewska A, Ciurtin C, Wedderburn LR, Rosser EC, Webb K, Deakin CT (2020) Male sex identified by global COVID-19 meta-analysis as a risk factor for death and ITU admission. *Nature Communications* 11:6317
23. Hill NR, Fatoba ST, Oke JL, Hirst JA, O’Callaghan CA, Lasserson DS, Hobbs FDR (2016) Global Prevalence of Chronic Kidney Disease – A Systematic Review and Meta-Analysis. *PLOS ONE* 11:e0158765

24. Kunutsor SK, Laukkanen JA (2020) Renal complications in COVID-19: a systematic review and meta-analysis. *Annals of Medicine* 52:345–353
25. Hansrivijit P, Qian C, Boonpheng B, Thongprayoon C, Vallabhajosyula S, Cheungpasitporn W, Ghahramani N (2020) Incidence of acute kidney injury and its association with mortality in patients with COVID-19: a meta-analysis. *Journal of Investigative Medicine* 68:1261–1270
26. Koye DN, Shaw JE, Reid CM, Atkins RC, Reutens AT, Magliano DJ (2017) Incidence of chronic kidney disease among people with diabetes: a systematic review of observational studies. *Diabetic Medicine* 34:887–901
27. Patschan D, Müller GA (2016) Acute Kidney Injury in Diabetes Mellitus. *International Journal of Nephrology* 2016:1–7
28. Oliveira CB, Lima CAD, Vajgel G, Campos Coelho AV, Sandrin-Garcia P (2021) High burden of acute kidney injury in COVID-19 pandemic: systematic review and meta-analysis. *Journal of Clinical Pathology* 74:796–803
29. Rodriguez VA, Bhawe S, Chen R, et al (2021) Development and validation of prediction models for mechanical ventilation, renal replacement therapy, and readmission in COVID-19 patients. *Journal of the American Medical Informatics Association* 28:1480–1488
30. Evans L, Rhodes A, Alhazzani W, et al (2021) Surviving sepsis campaign: international guidelines for management of sepsis and septic shock 2021. *Intensive Care Medicine* 47:1181–1247
31. Ponce D, Zorzenon C d. PF, Santos NY d., Balbi AL (2011) Early nephrology consultation can have an impact on outcome of acute kidney injury patients. *Nephrology Dialysis Transplantation* 26:3202–3206

